【 文献重点摘要 】
 

Background: Hyaluronic acid-based dermal fillers, such as hyaluronic acid gel (Restylane, Q-Medical AB, Uppsala, Sweden), are widely used for tissue augmentation of the nasolabial folds. Additional dermatologic treatments using infrared light, radiofrequency (RF), and intense pulsed light (IPL) are also important tools for facial rejuvenation. This study was designed to evaluate whether these therapies could be safely administered immediately after hyaluronic acid gel treatment without compromising the effect of the dermal filler.

Objective: The objective of this study was to confirm or refute any possible subtractive effects of augmentation of the nasolabial folds when followed by 1,320-nm Nd:YAG laser, 1,450-nm diode laser, monopolar RF, and/or IPL treatments.

Methods: Thirty-six patients with prominent nasolabial folds were treated with hyaluronic acid gel implantation on one side of the face and hyaluronic acid gel followed by one of the nonablative laser/RF/IPL therapies on the contralateral side of the face.

Results: There were no statistically significant differences between wrinkle severity or global aesthetic scores for hyaluronic acid gel implantation alone and hyaluronic acid gel with laser/RF/IPL treatment at any time point. In a small sample, histologic changes were not apparent after laser/RF/IPL treatment.

Conclusion: Based on this small pilot study, laser, RF, and IPL treatments can safely be administered immediately after hyaluronic acid gel implantation without reduction in overall clinical effect.

背景：透明质酸为基础的真皮填充物，如透明质酸凝胶(Restylane，Q-Medical AB，瑞典乌普萨拉)，被广泛用于鼻唇皱褶的组织增厚。使用红外线、射频(RF)和强脉冲光(IPL)的其他皮肤科治疗也是面部年轻化的重要工具。这项研究旨在评估这些疗法在透明质酸凝胶治疗后是否可以立即安全使用，而不会影响真皮填充剂的效果。

目的：本研究的目的是证实或驳斥1320 nm Nd：YAG激光、1450 nm半导体激光、单极射频和/或IPL治疗后鼻唇皱褶增大的任何可能的减影效应。方法：对36例鼻唇沟肥大患者采用一侧透明质酸凝胶植入，一侧透明质酸凝胶植入，对侧采用非消融性激光/射频/IPL治疗。

方法：对36例鼻唇沟肥大患者，一侧植入透明质酸凝胶，一侧植入透明质酸凝胶，对侧采用非消融性激光/RF/IPL治疗。

结果：单纯植入透明质酸凝胶与透明质酸凝胶联合激光/RF/IPL治疗的皱纹严重程度和整体美学评分在任何时间点均无统计学差异。在小样本中，激光/RF/IPL治疗后组织学改变不明显。

结论：基于这项小型先导性研究，透明质酸凝胶植入后立即进行激光、射频和IPL治疗是安全的，而不会降低总体临床疗效。